Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 5/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 5/20 | 1.00 |
| ▸ | GANC | Q8TET4 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 0.93 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.93 |
| ▸ | GBA1 | P04062 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654237 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1479404 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265529 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL2265531 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL9379987 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL1879685 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL20466285 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7824407 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL7811568 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA | |
| SCHEMBL18271004 | 1.00 | MGAM (1.00) | MGAMFUCA1GLAGANCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346262-A1 | Method of enhancing lysosomal alpha-Galactosidase A | ICAHN SCHOOL MED MOUNT SINAI (US) | 2016-12-01 | — | — | US | disclosed |
| US-9265780-B2 | Method of enhancing lysosomal α-galactosidase A | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140206718-A1 | Method of enhancing lysosomal alpha-Galactosidase A | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8633221-B2 | Method of enhancing lysosomal α-galactosidase A | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2014-01-21 | — | — | US | disclosed |
| US-20100137229-A1 | Method Of Enhancing Lysosomal Alpha-Galactosidase A | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2010-06-03 | — | — | US | disclosed |
| US-7622485-B2 | Method of enhancing lysosomal α-galactosidase A | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346262-A1 | Method of enhancing lysosomal alpha-Galactosidase A | GAA, GLA, MAN2B1 | MGAM 21/4885FUCA1 19/4885GLA 2/4885 |
| US-20140206718-A1 | Method of enhancing lysosomal alpha-Galactosidase A | GAA, GLA, MAN2B1 | MGAM 21/4885FUCA1 19/4885GLA 2/4885 |
| US-20100137229-A1 | Method Of Enhancing Lysosomal Alpha-Galactosidase A | GAA, GLA, MAN2B1 | MGAM 21/4885FUCA1 19/4885GLA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.